Study Finds Venetoclax Worsens Outcomes in Newly Diagnosed Double-Hit Lymphoma
Source Summary
A phase II randomized trial found that adding the BCL2 inhibitor venetoclax to chemoimmunotherapy resulted in worse outcomes and excess mortality in patients with newly diagnosed double-hit lymphoma. The study demonstrated that this combination approach did not improve patient survival compared to standard treatment.
Why it matters
This finding suggests that venetoclax should not be added to chemoimmunotherapy for newly diagnosed double-hit lymphoma patients, as it increases mortality risk rather than improving treatment outcomes.
